(PharmaNewsWire.Com, September 29, 2017 ) At present, there has been rising incidence of skin cancers in both developed and developing nations. With the advent in greater number of cures, the probabilities of higher diagnosis and treatments have increased manifold. A form of skin cancer, known as actinic keratosis is steadily rising around the world, which requires better treatment for people suffering from the disease. Market Research Hub (MRH) has recently broadcasted a study to its vast repository, which is titled as “Actinic Keratosis - Pipeline Review, H2 2017” and offers comprehensive information on the therapeutic under development for fatigue and overall pipeline landscape. The pipeline products described in this report have been analyzed on the basis of their development stage i.e. from pre-registration to discovery.
The first section of the report presents an overview of Actinic (Solar) Keratosis. This section also highlights the development of therapeutics, pipeline products utilized in actinic keratosis and a comparative analysis of these pipeline products. Actinic keratoses, also known as solar keratoses, are rough spots on skin caused by damage from years of sun exposure. Most commonly face areas exposed to the sun include nose & forehead, forearms, backs of hands in men, rims of ears, bald scalps, etc. The research also explains signs and symptoms of an actinic keratosis include a hard, wart-like surface, patch or bump on the top layer of skin, itching or burning in the affected area and color as varied as pink, red or brown, or flesh-colored.
Commonly, skin biopsy and physical observations are performed for diagnosis and confirmation of the actinic keratosis. About 5-20% of patients with actinic keratosis lesions develop malignant and potentially fatal squamous cell carcinoma, thus, early treatment of actinic keratosis is recommended to avoid this progression. Moreover, the analysts have conducted an assessment of fatigue therapeutics on the basis of molecule type, target, route of administration, and mechanism of action. Drugs such as 854-A, AM-001, celecoxib, AD-17137, GDC-695, hydrogen peroxide + sulindac, imiquimod SR, ingenol disoxate, LFX-453, ORIL are also studied in this report. According to the findings, market is majorly driven by wide presence of generic drugs available for the therapeutics.
For a competitive analysis, the research has listed key companies operating in the market, focusing on their research and development efforts, adoption to changing trends, and their efforts to discover new therapeutics for fatigue. At present, key players involved in the therapeutic development are Athenex Inc., G&E Herbal Biotechnology Co. Ltd., Novartis AG, Laboratories Ojer Pharma SL, Foamix Pharmaceuticals Ltd., Promius Pharma LLC, LEO Pharma A/S and Oncology Research International Ltd.
At present, there has been rising incidence of skin cancers in both developed and developing nations. With the advent in greater number of cures, the probabilities of higher diagnosis and treatments have increased manifold. A form of skin cancer, known as actinic keratosis is steadily rising around the world, which requires better treatment for people suffering from the disease. Market Research Hub (MRH) has recently broadcasted a study to its vast repository, which is titled as “Actinic (Solar) Keratosis - Pipeline Review, H2 2017” and offers comprehensive information on the therapeutic under development for fatigue and overall pipeline landscape. The pipeline products described in this report have been analyzed on the basis of their development stage i.e. from pre-registration to discovery.
The first section of the report presents an overview of Actinic (Solar) Keratosis. This section also highlights the development of therapeutics, pipeline products utilized in actinic keratosis and a comparative analysis of these pipeline products. Actinic keratoses, also known as solar keratoses, are rough spots on skin caused by damage from years of sun exposure. Most commonly face areas exposed to the sun include nose & forehead, forearms, backs of hands in men, rims of ears, bald scalps, etc. The research also explains signs and symptoms of an actinic keratosis include a hard, wart-like surface, patch or bump on the top layer of skin, itching or burning in the affected area and color as varied as pink, red or brown, or flesh-colored.
Commonly, skin biopsy and physical observations are performed for diagnosis and confirmation of the actinic keratosis. About 5-20% of patients with actinic keratosis lesions develop malignant and potentially fatal squamous cell carcinoma, thus, early treatment of actinic keratosis is recommended to avoid this progression.
Moreover, the analysts have conducted an assessment of fatigue therapeutics on the basis of molecule type, target, route of administration, and mechanism of action. Drugs such as 854-A, AM-001, celecoxib, AD-17137, GDC-695, hydrogen peroxide + sulindac, imiquimod SR, ingenol disoxate, LFX-453, ORIL are also studied in this report. According to the findings, market is majorly driven by wide presence of generic drugs available for the therapeutics.
For a competitive analysis, the research has listed key companies operating in the market, focusing on their research and development efforts, adoption to changing trends, and their efforts to discover new therapeutics for fatigue. At present, key players involved in the therapeutic development are Athenex Inc., G&E Herbal Biotechnology Co. Ltd., Novartis AG, Laboratories Ojer Pharma SL, Foamix Pharmaceuticals Ltd., Promius Pharma LLC, LEO Pharma A/S and Oncology Research International Ltd.
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
